Results 31 to 40 of about 93,898 (384)

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. [PDF]

Pharmaceuticals (Basel)
Maniscalco M, Ambrosino P, Candia C, Di Stefano A, Gnemmi I, Zappa M, Ambrosino N, Visca D, Motta A.   +8 more
europepmc   +2 more sources

Targeting eosinophils: severe asthma and beyond [PDF]

Drugs in Context, 2019
Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market.
Caminati, Marco, Menzella, Francesco, Guidolin, Lucia, Senna, Gianenrico   +3 more
openaire   +5 more sources

Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study

BMC Pulmonary Medicine, 2022
Background Eosinophilia is a significant factor in asthma severity; however, the prevalence of severe eosinophilic asthma in Saudi Arabia is largely unknown.
Hamdan Al-Jahdali, Siraj Wali, Amr S. Albanna, Riyad Allehebi, Hussein Al-Matar, Mohamed Fattouh, Maarten Beekman   +6 more
doaj   +1 more source

Successful treatment with dupilumab for mucus plugs in severe asthma

Respirology Case Reports, 2023
A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used a high dose of inhaled corticosteroids and a long‐acting beta‐2 agonists. Chest
Moriyasu Anai, Chieko Yoshida, Hiroki Izumi, Kei Muramoto, Koichi Saruwatari, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakagami   +7 more
doaj   +1 more source

Severe asthma: adding new evidence – Latin American Thoracic Society

ERJ Open Research, 2021
This document constitutes a summary of the clinical practice guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select six clinical questions,
Gabriel García, Miguel Bergna, Juan C. Vásquez, Maria C. Cano Salas, José L. Miguel, Carlos Celis Preciado, Agustin Acuña Izcaray, Manuel Barros Monge, Natalia García Batista, Ignacio Zabert, José L. Mayorga, Renato Casanova Mendoza, Martha Gutierrez, Maria F. Montero Arias, Luzcenelia Urtecho Perez, Miguel Antúnez, Victoria Williams Derby, Alejandra Villatoro Azméquita, Luis Motiño, M. Alenita De Oliveira, Diana Rey Sanchez, Marisol Arroyo, Mario Rodriguez   +22 more
doaj   +1 more source

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Respiratory Research, 2023
Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain.
A. Padilla-Galo, Isabel Moya Carmona, P. Ausín, L. Carazo Fernández, I. García-Moguel, José Luis Velasco-Garrido, R. Andújar-Espinosa, F. Casas-Maldonado, E. Martínez-Moragón, Carlos Martínez Rivera, Elisabet Vera Solsona, F. Sánchez-Toril López, A. Trisán Alonso, Marina Blanco Aparicio, M. Valverde-Monge, B. Valencia Azcona, Marta Palop Cervera, J. Nuevo, J. Sánchez Tena, G. Resler, Elisa Luzon, Alberto Levy Naón   +21 more
semanticscholar   +1 more source

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy

Pharmaceutics, 2023
The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis.
Diego Bagnasco, Edoardo Vincenzo Savarino, Mona-Rita Yacoub, Fulvio Braido, Maria Giulia Candeliere, Edoardo Giannini, Giovanni Passalacqua, Elisa Marabotto   +7 more
doaj   +1 more source

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Respiratory Research, 2023
Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects.
A. Vultaggio, M. Aliani, E. Altieri, P. Bracciale, L. Brussino, M. Caiaffa, P. Cameli, G. Canonica, C. Caruso, S. Centanni, M. D'Amato, F. De Michele, S. D. Del Giacco, F. Di Marco, F. Menzella, G. Pelaia, P. Rogliani, M. Romagnoli, Pietro Schino, G. Senna, Marco Benci, S. Boarino, J. Schroeder   +22 more
semanticscholar   +1 more source

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.

PLoS ONE, 2021
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi, Hironori Masuko, Yohei Yatagai, Takefumi Saito, Nobuyuki Hizawa   +10 more
doaj   +1 more source

Severe eosinophilic bronchial asthma: new therapeutic options

Медицинский совет, 2018
Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma ...
N. M. Nenasheva
doaj   +1 more source